FTC Intervenes In Teva-Amneal Row To Push Patent Delisting

By Bryan Koenig · March 25, 2024, 8:29 PM EDT

The Federal Trade Commission waded into another patent fight Friday with a New Jersey federal court amicus brief targeting the same Teva Pharmaceuticals asthma inhaler patents it has already included in...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief

Case Information

Case Title

TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. AMNEAL PHARMACEUTICALS OF NEW YORK, LLC et al

Case Number

Court

New Jersey

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

October 06, 2023

Recent Articles By Bryan

November 15, 2024
PBMs Denied Breakup Of Combined FTC Insulin Price Trial
November 13, 2024
Outgoing DOJ Antitrust Head Wants To Unstack Healthcare
November 12, 2024
HIV Drug Buyers Want Gilead Product Switch Claims Revived
November 12, 2024
Unsatisfied With $70M UTC Win, Sandoz Appeals To 3rd Circ.
November 07, 2024
Same PBM Conduct Means Same Insulin Price Trial, FTC Says
October 21, 2024
PBMs Keep Door Open To Constitutional Riposte Against FTC
October 16, 2024
Caremark, Optum Say FTC Insulin Case Gets PBMs All Wrong
October 15, 2024
'Extraordinary' Blue Cross Deal Includes $2.8B Payout
October 07, 2024
Merck Immune For 'Inflated' Vax Claims To FDA, 3rd Circ. Says
September 06, 2024
Actelion Must Face Tracleer Antitrust Suit With Class Certified